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Bcl-2 family proteins are involved in the cell homeostasis by regulating programmed cell death. Some of these proteins promote apoptosis,
while others inhibit the same process. The C-terminal hydrophobic domain of some of these proteins is predicted to be involved in anchoring them
to a variety of cell membranes, such as mitochondrial, endoplasmic reticulum and nuclear membranes. We have used five synthetic peptides
imitating the C-terminal domain from both anti-apoptotic (Bcl-2) and pro-apoptotic members (Bak, Bax, and two mutants of this last protein) of
this family to study their interaction with model membranes. Some differences were detected in the interaction with these peptides. The addition of
all the peptides to large unilamellar vesicles destabilized them and released encapsulated carboxyfluorescein to different degrees, so that fluidity
and the increase in negative curvature favoured the extent in the release of carboxyfluorescein. Bcl-2-C and Bax-C peptides produced the highest
release levels in most cases, while BaxS184K-C was the least efficient in this respect. These results indicate that these C-terminal domains are able
to insert themselves in the membranes, each in a different way that is probably related with their different way which can be related to their
differing locations within the cell and their different roles in regulating apoptosis.
© 2007 Elsevier B.V. All rights reserved.Keywords: Bcl-2; Bax; Bak; Apoptosis; Protein–lipid interaction; Fluorescence1. Introduction
Programmed cell death (apoptosis) controls normal tissue
homeostasis by balancing cell proliferation and removing dam-
aged, unwanted, aged and infected cells [1–3]. Alteration of the
normal apoptotic process is symptomatic of several human
diseases [4,5]. Due to its vital importance, apoptosis is a highly
regulated mechanism, the proteins of the Bcl-2 family being one
of the most important factors involved in such regulation since
they are responsible for integrating diverse survival and death
signals that are generated outside and inside the cell [6,7]. These
proteins can form homo- and heterodimers [8–10].Abbreviations: CF, 5(6)-carboxyfluorescein; DAG, diacylglycerol obtained
from egg yolk phosphatidylcholine; DPH, 1,6-diphenyl-1,3,5-hexatriene;
EYPC, egg yolk phosphatidylcholine; LUVs, large unilamellar vesicles;
MLVs, multilamellar vesicles; P, polarization of the emitted fluorescence;
TFE, 2,2,2-trifluoroethanol; THF, tetrahydrofuran
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doi:10.1016/j.bbamem.2007.08.014The multi-BH domain family members are either anti- or pro-
apoptotic proteins. In general, the anti-apoptotic members (e.g.,
Bcl-2, Bcl-xL, Mcl-1, Bcl-w from mammals and Ced-9 from
Caenorhabditis elegans) display sequence homology in all four
BH domains, whereas the pro-apoptotic members (e.g., Bax,
Bak and Bok) have homologous BH1–3 domains. Pro-apoptotic
Bcl-2 family members, upon activation by apoptotic stimuli, are
capable of forming heterodimers with anti-apoptotic members.
The solution structure of Bcl-xL reveals that the BH1–3 domains
of Bcl-xL form an elongated hydrophobic groove, which is the
docking site for the BH3 domains of pro-apoptotic binding
partners [11-12].
In addition to BH domains, many of these proteins contain a
hydrophobic transmembrane domain (TMD) at their carboxy
terminus. This C-terminal domain is supposedly responsible for
membrane localization, for example, in the outer membrane of
mitochondria, the nucleus or in the endoplasmic reticulum
membranes [13–18], indicating that these proteins may exist as
integral membrane proteins [19–21]. The pattern of membrane
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this sense, Bcl-2 has been shown to reside on the cytoplasmic
face of the mitochondrial outer membrane, whereas Bax or Bid
is found mainly in the cytosol or as membrane peripherals in
healthy living cells, and only interacts with the mitochondrial
membrane when they are activated [22–25].
Some of the Bcl-2 family members have been cloned and
expressed for studies at high resolution. However, many of
these studies used truncated forms which do not include the
hydrophobic C-terminal domain in order to obtain the high
quantities of soluble protein required for the structural studies,
because full proteins are of impaired solubility. Nevertheless,
the structures of a few full-length proteins have been deter-
mined, and in all cases, the C-terminal segments were shown to
fold back onto a groove on the structures, similarly to Bax [26].
Homeostasis is maintained by controlling the amount of
active pro- and anti-apoptotic family members in different tis-
sues. The ratio between pro- and anti-apoptotic proteins helps to
determine, in part, the susceptibility of cells to a death signal
and, when called for, programmed cell death. These apoptotic
signals target various intracellular components, including the
pro-apoptotic Bcl-2 members.
The hydrophobic C-terminal domain is, it is supposed, very
important in targeting these proteins to differing cell mem-
branes, as mentioned above. In this sense, a comparative studyFig. 1. Classification of the Bcl-2 family, showing the most important member of eac
transmembrane domain (CTD) are drawn. The position of α-helices and the functio
terminal peptides used in this study are also displayed.of different C-terminal domains of pro- and anti-apoptotic Bcl-2
proteins would be very interesting to help elucidate the role of
each one. In the present study, we have used five synthetic
peptides imitating the C-terminal domain of some of the Bcl-2
family proteins, namely Bcl-2-C, Bak-C, Bax-C and two mu-
tants of this last protein (Fig. 1), and studied their interaction
with different model membranes and their ability to disrupt
membrane barrier properties using fluorescence spectroscopy.
The results showed that the interaction of each peptide with the
model membranes, as seen through the release of encapsulated
carboxyfluorescein, differed, with Bcl-2-C and BaxS184K-C
showing the weakest effects.
2. Materials and methods
2.1. Materials
The synthetic Bcl-2 C-terminal domain peptide (Bcl-2-C) encompassed
residues 217–239 of Bcl-2 (+3HN-
217LTKLLSLALVGACITLGAYLGHK239-
COO−), whereas the synthetic Bak C-terminal domain peptide (Bak-C) included
residues 188–211 of Bak (+3HN-
188ILNVLVVLGVVLLGQFVVRRFFKS211-
COO−). The three remaining synthetic peptides were related, because one, the
Bax C-terminal domain peptide (Bax-C), encompassed residues 172–192 of
Bax (+3HN-
172TVTIFVAGVLTASLTIWKKMG192-COO−) and the other two
were mutants of the previous one, so that Ser184 was replaced by Lys184 (Bax
S184K-C) and in the second Ser184 was deleted (BaxΔS184-C). The five
synthetic peptides were purchased from Genemed (San Francisco, CA, USA)h subfamily. Bcl-2 homology domains (BH) 1 to 4, and hydrophobic C-terminal
n of the most important regions are also shown. The sequences of the carboxy
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TOF spectroscopy carried out by the manufacturer.
Egg yolk phosphatidylcholine (EYPC), cholesterol (Chol) and egg yolk
sphingomyelin (SM) were purchased from Avanti Polar Lipids, Inc. (Alabaster,
AL, USA). Egg yolk diacylglycerol (DAG) was prepared from egg yolk phos-
phatidylcholine by the action of phospholipase C (Bacillus cereus, Sigma
Chemicals Co., Madrid, Spain) as previously described [27]. 11,6-Diphenyl-
1,3,5-hexatriene (DPH), 2,2,2-trifluoroethanol (TFE), and Triton X-100 were
obtained from Sigma Chemicals Co. (Madrid, Spain). 5(6)-Carboxyfluorescein
(CF) was obtained from Kodak (Eastman Kodak Co., Rochester, NY, USA). The
other solvents were from Merck (Darmstadt, Germany) and all other reagents
used in this work were of analytical grade. Water was twice distilled and
deionized using a Millipore system from Millipore Ibérica (Madrid, Spain). All
fluorescence experiments were performed using a Fluoromax-3 fluorescence
spectrophotometer (Jobin Yvon, Longjumeau, France).
2.2. Preparation of lipid mixtures for the leakage experiments
Lipid vesicles were generated by mixing chloroform solutions of the dif-
ferent lipids at the desired molar proportions. Lipid mixtures were dried under a
stream of oxygen-free nitrogen, and then the last traces of organic solvents were
removed by a further 3-h evaporation under high vacuum. Dried lipids were
resuspended in the corresponding buffers by vigorous vortexing in the liquid-
crystalline phase, i.e., above the transition temperature of the lipid mixture, to
produce multilamellar vesicles (MLVs). These vesicles were used in the fluore-
scence polarization experiments.
In the case of fluorescence carboxyfluorescein leakage, large unilamellar
vesicles (LUVs) were used. These were prepared using the extrusion technique
[28,29]. Briefly, MLVs were frozen and thawed at 30 °C (temperature above
the transition temperature of the lipid mixtures) five times and then the sus-
pensions were extruded 10 times through two stacked 100-nm polycarbonate
filters (Millipore Inc., Bedford, USA).
The quantification of the lipids was carried out in according to Böttcher et al.
[30].
2.3. Leakage of liposome contents
Leakage of the liposome content to the external medium was kinetically
monitored by measuring the release of the 5(6)-carboxyfluorescein (CF) trapped
inside the vesicles [31–34]. The fluorescence dye (CF) was purified by gel
filtration on a Sephadex LH-20 (1×30) column in 10 mM HEPES pH 7.4 buffer
and stored at 4 °C in the dark.
Lipid mixtures were hydrated in a 50-mM Mes pH 7.4, 50 mM K2SO4
buffer, containing 50 mM purified CF [32]. LUVs were prepared and purified as
previously described [35].
The increase in CF fluorescence upon CF release was followed using an
excitation wavelength of 492 nm (5-nm slit width) and monitoring the emission
intensity at 520 nm (10-nm slit width). Measurements were made in a thermo-
stated quartz cuvette with constant stirring at 25 °C. Each sample contained
10 μM LUVs in 2 ml of 50 mMMes pH 7.4, 100 mM K2SO4 buffer. A baseline
measurement of the fluorescence of the vesicles alone was made for 15 min. In
our experimental conditions the spontaneous leakage rate was b5%. Then the
different peptides were dissolved in TFE at 2 or 0.5 mg/ml and added to the
solution. Different volumes of TFE alone were also added to check the leakage
produced by this organic solvent. The addition of up to 4 μl of TFE did not
produce any substantial additional leakage. After adding of the peptides, fluore-
scence wasmonitored for 15min, and then a small volume of concentrated Triton
X-100 (final concentration 0.5%, w/v) was added to determine the maximum
fluorescence attainable under conditions of totally solubilized vesicles. The
percentage of CF released was determined by the following equation:
ðFt¼15 min  F0Þ
ðFmax  F0Þ  100
where Ft=15 min is the maximum fluorescence intensity 15 min after the addition
of the peptide or TFE, F0 is the fluorescence intensity of vesicles alone at time 0,
and Fmax is the fluorescence intensity after the addition of Triton X-100.2.4. Binding of peptides to lipid vesicles
Samples were prepared from lipid stocks dissolved in chloroform and
peptide stocks dissolved in 2,2,2-trifluoroethanol (TFE). A total of 100 μg of
peptides and the appropriate quantity of lipids to obtain a molar peptide–lipid
ratio of 0.02 were dried under a stream of nitrogen. The last traces of solvent
were removed by evaporation under high vacuum for at least 2 h. Then
200 μl of TFE was added and the samples were vortexed and dried again in
the same way as previously described. Samples were hydrated in 400 μl of
buffer containing 50 mM MES, 50 mM K2SO4 pH 7.4. Once formed,
vesicles were centrifuged and the liposome phase at the top and the
supernatant was separated from the precipitated peptides [36]. The
phospholipid phase and the supernatant were centrifuged again in the same
conditions and finally the supernatant was removed with a syringe. Samples
were dissolved in 400 μl of TFE/formic acid (99.5:0.5) and injected into the
HPLC/MS system.
The quantification analysis was carried out on an HPLC/MS system con-
sisting of an Agilent 1100 Series HPLC (Agilent Technologies, Santa Clara, CA,
USA) equipped with a quaternary pump, a thermostated μ-wellplate autosam-
pler, and a DAD module connected to an Agilent Ion Trap XCT Plus Mass
Spectrometer (Agilent Technologies, Santa Clara, CA, USA) using an electro-
spray (ESI) interface.
Samples and standards with known concentrations of each peptide were
prepared by dissolving 100 μg each peptide in 400 μl of TFE/formic acid
(99.5:0.5) and injected into a Supelco Discovery C18 HPLC column (5 μm,
100×2.1 mm, Supelco, Pennsylvania, USA). The column was thermostated at
40 °C, and the peptides were eluted at a flow rate of 0.1 ml/min. Mobile phase A
(99.5:0.5, water/formic acid) and mobile phase B (99.5:0.5 methanol/formic
acid) were used for the chromatographic separation. The elution consisted of
5 min of 10% B, and a linear gradient from 10 to 100% B in 10 min. 100%Bwas
maintained for 10 min. The column was equilibrated with the starting composi-
tion of the mobile phase (10% B) for 20 min before each analytical run. The UV
signal at 280 nm was recorded. The mass spectrometer was operated in the
positive mode with a capillary spray voltage of 3500 V and a scan speed of
26,000 (m/z)/s from 200–3200 m/z. The nebulizer gas (He) pressure was set to
30 psi, whereas the drying gas was set to a flow of 8 l/min at a temperature of
350 °C.
The peptides were quantified using both the UV and the extracted ion
chromatogram of the most intense peptide ion. Calibration curves were calcu-
lated with known standard concentrations of each peptide. The peak area of both
UV and extracted ion chromatogram was quantified using the DataAnalysis
program for LC/MSD Trap Version 3.2 (Bruker Daltonik, GmbH, Germany).
Similar results were obtained when using the UV and the mass spectroscopy
detectors. The results shown are those from the mass spectrometry.
2.5. Laser light scattering measurements
LUVs' size was measured by means of a Malvern Autosizer 4800 Spectro-
meter (240 V) equipped with a RR98 pump/filter unit. Samples were measured
at a temperature of 25 °C and at a wavelength of 488 nm. The scattering angle
was set at 90° and the proportions of the solvent were refractive index 1.33 and
viscosity 0.95 cP. The vesicle sizes were recorded in the absence and in the
presence of each peptide, which when present gave a peptide–lipid molar ratio
of 0.02.
2.6. Fluorescence polarization
MLVs including the fluorescent probe 1,6-diphenyl-1,3,5-hexatriene
(DPH) at a lipid/probe molar ratio of 500:1 were prepared in 10 mM
HEPES pH 7.4, 0.1 mM EDTA filtered buffer as previously described [35].
Three independent samples including 20 nmol of total lipid of each mixture
were analyzed.
DPH fluorescence polarization was measured using excitation and emission
wavelengths of 350 and 452 nm, respectively, with a slit width of 5 nm for both
excitation and emission. Fluorescence polarization was measured at a constant
temperature of 25 °C with continuous stirring inside the cuvette in order to
prevent the settling of the vesicles. In the fluorescence polarization experiment,
the sample was excited with a polarized beam, and the components of the
Table 1
Incorporation of C-terminal domains into vesicles expressed as molar peptide/lipid ratios
Lipid mixture Bak-C Bax-C BaxΔS184-C BaxS184K-C Bcl-2-C
EYPC 9.74±0.29 6.59±0.29 8.67±0.09 9.73±0.24 5.54±0.25
EYPC+POG (9:1) 10.23±0.22 5.04±0.13 10.35±0.11 5.53±0.40 6.83±0.22
EYPC+Chol (4:1) 13.13±0.34 4.45±0.25 11.75±0.40 5.13±0.09 5.09±0.29
EYPC+SM (4:1) 7.92±0.14 2.94±0.05 9.57±0.30 4.50±0.15 4.83±0.21
EYPC+Cyclosporin A (9:1) 10.87±0.40 5.97±0.04 12.63±0.12 6.70±0.17 9.48±0.57
The values were multiplied by a factor of 103. Three independent experiments were carried out.
Table 2
LUV sizes in absence and in presence of the different peptides
Lipid mixture LUV size
(nm)
LUV+peptide size
(nm)
EYPC+Bak-C 104.4±3.02×10−4 117.4±1.69×10−4
EYPC+Bax-C 104.5±1.36×10−4 108.8±1.03×10−4
EYPC+BaxΔS184-C 104.0±2.04×10−4 112.1±1.78×10−4
EYPC+BaxS184K-C 103.0±1.65×10−4 109.2±1.59×10−4
EYPC+Bcl-2-C 105.9±1.62×10−4 116.7±1.11×10−4
EYPC/POG (9:1)+Bak-C 86.4±1.49×10−4 93.6±1.26×10−4
EYPC/POG (9:1)+Bax-C 85.5±2.01×10−4 86.7±2.47×10−4
EYPC/POG (9:1)+BaxΔS184-C 87.0±2.22×10−4 98.2±1.47×10−4
EYPC/POG (9:1)+BaxS184K-C 85.4±1.76×10−4 88.1±1.31×10−4
EYPC/POG (9:1)+Bcl-2-C 84.3±2.15×10−4 93.3±1.29×10−4
EYPC/Chol (4:1)+Bak-C 105.3±1.98×10−4 108.4±1.90×10−4
EYPC/Chol (4:1)+Bax-C 106.0±2.17×10−4 109.9±1.78×10−4
EYPC/Chol (4:1)+BaxΔS184-C 104.5±1.93×10−4 111.6±2.29×10−4
EYPC/Chol (4:1)+BaxS184K-C 106.0±1.81×10−4 110.4±1.79×10−4
EYPC/Chol (4:1)+Bcl-2-C 106.9±2.13×10−4 109.6±2.32×10−4
EYPC/SM (4:1)+Bak-C 105.2±1.55×10−4 116.5±1.54×10−4
EYPC/SM (4:1)+Bax-C 102.2±1.75×10−4 106.2±1.60×10−4
EYPC/SM (4:1)+BaxΔS184-C 100.4±1.71×10−4 107.4±1.30×10−4
EYPC/SM (4:1)+BaxS184K-C 103.8±1.92×10−4 111.6±1.55×10−4
EYPC/SM (4:1)+Bcl-2-C 104.5±2.59×10−4 118.6±1.99×10−4
EYPC/Cyclosporin A (9:1)+Bak-C 93.3±1.79×10−4 106.4±1.71×10−4
EYPC/Cyclosporin A (9:1)+Bax-C 86.0±1.56×10−4 92.3±1.71×10−4
EYPC/Cyclosporin A (9:1)+
BaxΔS184-C
86.5±1.21×10−4 92.8±1.80×10−4
EYPC/Cyclosporin A (9:1)+
BaxS184K-C
90.9±1.61×10−4 97.6±1.70×10−4
EYPC/Cyclosporin A (9:1)+
Bcl-2-C
94.3±1.60×10−4 112.4±1.38×10−4
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measured. The polarization of the emitted fluorescence, P, was determined as
P ¼ 1 ½ðI90;0=I90;90Þ  ðI0;90=I0;0Þ
1þ ½ðI90;0=I90;90Þ  ðI0;90=I0;0Þ
where a correction factor for the instrumental response of the two components of
emission has been applied [37]. I90,0 is the fluorescence intensity when the
excitation polarizer is perpendicular to the direction of the beam and the emission
is parallel; I90,90 and I0,0, when both are perpendicular or parallel, respectively;
and I0,90, when the excitation polarizer is parallel while the emission polarizer is
perpendicular to the direction of the beam. To ensure that there was no pola-
rization due to light scattering, polarization was measured before and after
sample dilution. In cases when dilution led to an increased level of P, the samples
were diluted until the value of P remained constant.
3. Results
3.1. Ability of the C-domains to incorporate into membranes
It is interesting to compare the different C-domains with
respect to their capacity to incorporate into membranes con-
taining different lipids. This was analyzed after the addition of
peptides to preformed vesicles and centrifugation of the vesicles
and flotation in 2H2O buffer, at a peptide to lipid molar ratio of
0.02 [36]. Table 1 shows that in the case of Bak-C the level of
peptide incorporation was quite similar for EYPC, EYPC plus
10 mol% of POG and in the presence of 10 mol% of cyclosporin
A. Incorporation was greater, however, after the addition of
cholesterol, while it decreased slightly after the addition of SM.
In the case of Bax-C, very similar levels of incorporation
were observed for EYPC alone and in the presence of cyclos-
porin A. A reduced level was detected in the case of POG,
cholesterol and particularly in the case of SM.
As regards BaxΔS184-C, peptide incorporation was slightly
higher after the addition of POG and SM than in the presence
of pure EYPC, with cholesterol and cyclosporin A permitting
higher increases.
In contrast, when BaxS184K-C was studied, the addition of
other membrane components to EYPC led to a decrease in
incorporation in all cases, particularly in the case of SM.
Finally, when Bcl-2-C was studied, the only addition which
significantly modified the level of incorporation was cyclos-
porin A, which led to a substantial increase.
3.2. Effect of incorporating C-terminal domains on the sizes of
lipid vesicles
The interaction of the C-terminal domains with the different
membranes may have as a consequence their macroscopicchange due to fusion or important morphologic rearrangements.
These changes can be monitored by laser light scattering which
reports on the size distribution of the vesicles. Table 2 shows that
the size of the vesicles was very similar in all cases and was not
greatly modified by the addition of the peptides. Variations in
size did not exceed 15% in any case, and therefore no substantial
changes in morphology were detected.
3.3. 6-Carboxyfluorescein leakage induced by C-terminal
domain peptides from Bcl-2 family of proteins
To assess the interaction of the peptides in the LUV model
membranes used in this study, the release of encapsulated 5(6)-
carboxyfluorescein (CF) trapped inside the vesicles was moni-
tored at 25 °C. The time course of a typical experiment with egg
yolk PC LUV and Bak-C peptide is shown in Fig. 2. It can be
seen that dye leakage started very soon after peptide addition,
Fig. 2. Time course leakage of carboxyfluorescein (CF) from EYPC LUVs at
25 °C. The release of CF was followed for 15 min. Point 1 marks the addition of
Bak-C peptide, whereas point 2 shows the lysis of vesicles after the addition of
Triton X-100.
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time was therefore taken as a reference for comparing the effect
of the different peptides. Triton X-100 was added at the end of
the experiment to release the rest of CF.Fig. 3. Leakage of carboxyfluorescein (CF) from different model membranes
(LUVs) induced by Bak-C (panel A) and Bcl-2-C (panel B). The lipid mixtures
used were EYPC (●), EYPC/DAG (9:1 molar ratio) (○), EYPC/Chol (4:1 molar
ratio) (▴), EYPC/SM (4:1 molar ratio) (▵), and EYPC/cyclosporin (9:1 molar
ratio) (▪). The percentage of CF released after 15 min of incubation with
increasing concentrations of peptide was plotted as a function of the peptide–
lipid molar ratio (c). 100% of CF leakage was established by lysing LUVs with
Triton X-100 (0.5%, w/v). Error bars indicate the SEM for triplicate independent
determinations. The solid lines show the best fit to data.
Fig. 4. Leakage of carboxyfluorescein (CF) from different model membranes
(LUVs) induced by Bax-C (panel A), BaxΔS184-C (panel B), and BaxS184K-C
(panel C). The lipid mixtures used were EYPC (●), EYPC/DAG (9:1 molar
ratio) (○), EYPC/Chol (4:1 molar ratio) (▴), EYPC/SM (4:1 molar ratio) (▵),
and EYPC/cyclosporin (9:1 molar ratio) (▪). The percentage of CF released
after 15 min of incubation with increasing concentrations of peptide was plotted
as a function of the peptide–lipid molar ratio (c). 100% of CF leakage was
established by lysing LUVs with Triton X-100 (0.5%, w/v). Error bars indicate
the SEM for triplicate independent determinations. The solid lines show the best
fit to the data.In the following experiments, CF release was measured with
increasing concentrations of each peptide. The percentage of CF
released 15 min after the addition of each peptide concentration
is depicted in Figs. 3 and 4. Table 3 shows the percentage of CF
released at a peptide–lipid molar ratio of 0.02. Nevertheless, the
results have been corrected according to the actual quantities of
peptides incorporated and expressed in percent of CF released
by 0.1 ng of peptide. The results showed that, with respect to
pure EYPC, only DAG increased the rate of dye release, with all
Table 3
CF leakage percentage with respect to the amount of incorporated peptides (percent of leakage of CF/0.1 nmol of incorporated peptide)
Lipid mixture Bak-C Bax-C BaxΔS184-C BaxS184K-C Bcl-2-C
EYPC 31.8±2.3 36.4±2.5 35.4±1.2 23.0±2.3 44.1±2.7
EYPC+POG (9:1) 37.2±1.4 69.3±2.9 38.8±1.0 63.1±5.2 57.0±3.8
EYPC+Chol (4:1) 20.3±1.2 30.7±3.7 26.1±1.4 29.6±2.5 45.6±3.6
EYPC+SM (4:1) 27.4±1.9 17.9±1.7 21.8±1.3 20.1±3.9 39.3±3.5
EYPC+Cyclosporin A (9:1) 13.6±1.5 9.9±0.5 12.2±0.5 8.4±0.7 10.3±1.1
Each peptide was added to give a peptide to lipid molar ratio of 0.02 and the actual amount of peptide incorporated was determined and used to calculate the values
shown.
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values of release which are not corrected for the actual quantity
of peptide incorporated into the vesicles, qualitatively the re-
sults are the same than after correcting for this incorporation, as
seen in Table 3.
The addition of the C-terminal domain peptide from Bcl-2
and Bak (Fig. 3) and from Bax, BaxΔS184 and BaxS184K
(Fig. 4) had different effects, depending on the type of vesicles
used. In the case of Bak-C (Fig. 3A), only the addition of DAG
(EYPC/DAG, 9:1 molar ratio) produced an increase in the
percentage of CF release with respect to pure EYPC vesicles. In
this way, whereas in the case of EYPC vesicles the release was
31.8%, this increased to 37.2% in the presence of DAG. All the
other additions caused a reduction in the release, with 20.3%,
27.4% and 13.6% produced by the addition of cholesterol
(EYPC/chol, 4:1 molar ratio), sphingomyelin (EYPC/SM, 4:1
molar ratio) and cyclosporin A (EYPC/cyclosporin A, 9:1 molar
ratio), respectively, to the EYPC vesicles.
Qualitatively similar results were obtained for the other four
peptides (Table 3 and Figs. 3 and 4), with DAG increasing the
amount of dye release and the other three additives decreasing
this release. The minimum release values were observed for
cyclosporin A with all five peptides, values as low as 13.6%,
9.9%, 12.2% 8.4% and 10.3% being obtained for Bak-C, Bax-
C, BaxΔS184-C, BaxS184K-C and Bcl-2-C, respectively.
When the five peptides added to pure EYPC vesicles were
compared (Table 3), it was observed that the maximum release
was obtained for Bcl-2-C (44.1%) and Bax-C (36.4%), while
the minimum release corresponded to BaxS184K-C (23.0%).
Qualitatively similar results were obtained when comparing the
peptides added to the other four types of membrane.
3.4. Fluorescence polarization of diphenyl hexatriene
The steady-state polarization value (P) provides a time-
averaged indication of the mobility of a fluorophore. DPH is a
hydrophobic fluorescent molecule which, when incorporated
into a lipid bilayer, is located in the hydrophobic region. When a
lipid mixture is above its transition temperature, i.e., in the fluid
phase, DPH is freely mobile, and its fluorescence is minimally
polarized. This probe has been widely used to study the effect of
proteins on membrane order [38]. Higher values of polarization
show a decrease in the mobility of the probe. In order to assess
the possible origin of the different effects produced by each
peptide on the membranes, the steady-state polarization (P) of
each lipid mixture was measured at 25 °C.The results showed that whereas P was 0.183±0.015 (three
different experiments), the addition of DAG (EYPC/DAG, 9:1
molar ratio) did not significantly modify this value (0.182±
0.012). However, there were significant increases in P after the
other three additions: 0.223±0.008 for EYPC/Chol (4:1 molar
ratio), 0.210±0.016 for EYPC/SM (4:1 molar ratio) and 0.238±
0.013 for EYPC/cyclosporin A (9:1 molar ratio). These data
suggest that the differing effects of the peptides on the stability
of the membranes used here are related with the difference
between their respective fluidities.
4. Discussion
Taking into account that the CF released was different for
each peptide with each lipid mixture, these data as a whole
suggest that themost affectedmembrane contained EYPC/DAG,
while the membrane including cholesterol was the least affected,
i.e., the most stable in the presence of the peptides. On the other
hand, when all the peptides are compared, the data suggest that
Bcl-2-C and Bax-C permitted the highest CF release values,
while BaxS184K-C was the least efficient in this respect. This
may be related with the differing capacity to span the membrane
of these domains. It has been shown before [39] that the sub-
stitution S184K produces a Bax-C form with a charged amino
acyl chain located in the middle of the hydrophobic stretch and
hence its capacity to span the membrane is greatly reduced. The
present results indicate that the peptides may differentially
disrupt the barrier properties of the phospholipid bilayer as a
function of their ability to span the membrane. Bax has been
shown to form multispanning monomers that oligomerize to
permeabilize membranes during apoptosis and inserts into the
membrane through the pore domain (helices α5-α6) and also the
C-domain (helix α9) [40]. The in vivo importance of residue
S184 to determine mitochondrial localization of Bax has been
shown before, when mutation S184K led to a diffuse cytoplas-
mic localization of Bax [41].
In the case of Bcl-2-C [35] and Bak-C [42], it has previously
been shown that they form α-helices with an orientation nearly
perpendicular to the plane of the membrane in the case of
membranes of reduced thickness (like DMPC) but form random
structures which do not span themembrane when the thickness is
greater [43]. In fact, the membranes used in this work are thick
enough to avoid the formation of spanning α-helices by both
Bcl-2-C and Bak-C. Therefore, small changes in the membrane
properties are essential for determining whether they will or not
be able to destabilize the barrier properties of the bilayer. It
2937A. Torrecillas et al. / Biochimica et Biophysica Acta 1768 (2007) 2931–2939should be remarked that Bak-C shows a higher destabilizing
capacity than Bcl-2-C in most of the membranes studied, as
measured by the release of CF, except in the presence of DAG,
when both domains behaved similarly.
The differences in the effects produced by the four additives
tested can be explained by their capacity to modulate membrane
structure. Due to the small size of its polar group, DAG pro-
duces several effects in the membrane (reviewed in [44]), in-
cluding enhancing the tendency of the membrane to adopt
nonbilayer structures [45], such as lipidic particles [44], spacing
the polar head groups of the phospholipids [46] and dehydration
of the membrane surface [47]. All these effects facilitate the
insertion of proteins in the membrane and will therefore en-
hance the destabilization of the lipid bilayer, which is necessary
for dye release. Cholesterol modulates membrane fluidity [48]
and, when added to a fluid membrane like that of EYPC, will
decrease this fluidity and increase membrane stability, as is
shown by our fluorescence probe polarization measurements.
Hence the presence of cholesterol is expected to decrease the
capacity of the peptides to induce CF release. The sphingo-
myelin used here has a high percentage of saturated ester acyl
chains (80% of palmitic) and so it, too, decreases membrane
fluidity, as was also shown by our fluorescence polarization
measurements. Finally, cyclosporin A is known to produce
positive curvature in the membrane [49] and therefore has an
opposite effect to DAG, hindering peptide insertion of the
peptides in the membrane. Additionally, fluorescence polariza-
tion shows that cyclosporin A has the additional effect of
reducing membrane fluidity, which would explain its drastic
effect on CF release.
The insertion of other proteins in the membrane has been
shown to be regulated by membrane curvature and/or fluidity, as
is the case with cytochrome b5 [50], ArfGAP1 [51], PI-specific
phospholipase C [52] and aerolysin [53], among many others,
and also by specific interactions with some phospholipids such
as protein kinase C [54,55]. It has also been suggested that Bax-
type proteins change the bending propensity of the membrane to
form pores comprised, at least partially, of lipids in a structure of
net positive monolayer curvature [36]. This suggestion was
made when using the full proteins and is clearly not the same
mechanism at that operating for the C-terminal domains. Our
results suggest, rather, that these peptides insert themselves in
the membrane, forming a pore, and that DAG (which increases
negative curvature) favours this process, whereas cyclosporin
A, which increases positive curvature, and cholesterol, SM and
the same cyclosporin A which decrease fluidity, hinder the
insertion in the membrane of the peptides in the membrane and
hence decrease the release of vesicle contents.
Studies with natural cytotoxic peptides [56] and with some
synthetic peptides of amphipathic nature (see for exampleGALA
[57]) have revealed that they may facilitate the release of en-
capsulated carboxyfluorescein, because they self-associate with-
in the membrane producing pores. Our results clearly show that
the C-terminal domains of Bcl-2 proteins also have this capacity.
It has been proposed that the C-terminal domain of pro-apoptotic
Bax inserts itself in the membrane where, together with α5 and
α6, it oligomerizes to produce pores [40]. In the case of otherproteins like anti-apoptotic Bcl-2, it has been observed that it
may form pores which are linked to the diffusion of ions such as
H+ through the mitochondrial membranes [58]. This protein
lacking the C-terminal domain may also form channels in lipidic
membranes [59,60]. The whole Bcl-2 protein has not been used
in this type of experiment with model membranes because of the
difficulties involved in producing it in a soluble form. Never-
theless, by analogy with Bax [26] and Bcl-w [61], it is tempting
to predict that the C-terminal domain of Bcl-2 may also con-
tribute to the formation of pores in biomembranes, and the same
can be said with respect to Bak. Certainly the results obtained in
this paper lend weight to this possibility.
According to our results, insertion of proteins of the Bcl-2
family into the membrane of the C-terminal domains may
function as pores, a role that is regulated by the lipid compo-
sition and hence by changes occurring as a consequence of cell
stimulation. Therefore, a given cell membrane may be more
suitable than others for anchoring these proteins. This may
have physiological significance when trying to explain the
preference observed in vivo for a given cellular localization. It
has recently been described that, at least in the endoplasmic
reticulum of yeast, there is a receptor, independent of ATP
hydrolysis, which may catalyze the incorporation into
membranes of proteins containing a transmembrane C-terminal
domain [62]. It remains to be seen whether such a receptor is
also present in other organisms and in other organelles, as in
mitochondria. Whatever the case is, interaction with lipids will
always be a part of the translocation process, and this has been
recognized in the case of cytochrome b5 [50]. In the case of
Bax, the 3D structure was determined for the full-length
protein, and it was seen that the C-terminal segment folds back
into a hydrophobic groove formed by the other BH domains
[26]. When cell signalling targets Bax, a conformational
change will displace the C-terminal domain from hydrophobic
groove and the interaction of Bax proteins with membranes
and with other proteins will now be possible. The interaction
of the C-terminal domain with lipids may then stabilize this
open and active conformation of Bax.
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